CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
|Webinars|May 6, 2022
Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care? Part 3
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
Advertisement
In this webinar from The American Journal of Managed Care®'s Oncology Value Coalition, experts from The US Oncology Network discussed the future of value-based cancer care.
Despite many successes, the Oncology Care Model (OCM) is set to expire in July 2022, with no replacement on the horizon. That doesn't mean the lessons of the OCM will be forgotten, but continuing the quality care efforts will be difficult. How will practices continue team-based care, patient navigation, and other enhanced services?
The speakers were:
- Rhonda Henschel, senior director of payer solutions, The US Oncology Network
- Ben Jones, vice president of government relations and public policy
McKesson Specialty Provider Organization, The US Oncology Network - Stuart Staggs, senior director of strategic programs, The US Oncology Network
- Lalan Wilfong, MD,vice president of payer relations and practice transformation, The US Oncology Network
In segment 3, they discussed oncology drugs in value-based care.
Advertisement
Related to this article
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Labial gland biopsy may support diagnosis of neurologic Sjögren disease, especially when antibody tests are negative or inconclusive.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
4
Consensus Helps Dermatologists Spot CTCL Mimicking Atopic Dermatitis on Dupilumab
5